Cargando…
Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children
BACKGROUND: Hemoglobin E beta-thalassemia (β-thalassemia/Hb E) has a variable severity, and the cost of treatment has not been well studied. The aim of this study was to analyze the societal cost of caring for children with β-thalassemias in Thailand. The study was designed as a prevalence-based cos...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835719/ https://www.ncbi.nlm.nih.gov/pubmed/20181056 http://dx.doi.org/10.1186/1756-0500-3-29 |
_version_ | 1782178656252067840 |
---|---|
author | Riewpaiboon, Arthorn Nuchprayoon, Issarang Torcharus, Kitti Indaratna, Kaemthong Thavorncharoensap, Montarat Ubol, Bang-on |
author_facet | Riewpaiboon, Arthorn Nuchprayoon, Issarang Torcharus, Kitti Indaratna, Kaemthong Thavorncharoensap, Montarat Ubol, Bang-on |
author_sort | Riewpaiboon, Arthorn |
collection | PubMed |
description | BACKGROUND: Hemoglobin E beta-thalassemia (β-thalassemia/Hb E) has a variable severity, and the cost of treatment has not been well studied. The aim of this study was to analyze the societal cost of caring for children with β-thalassemias in Thailand. The study was designed as a prevalence-based cost-of-illness analysis in a societal perspective. Medical records from three public hospitals of children aged 2-18 years with β-thalassemia/Hb E and homozygous β-thalassemia were reviewed for direct medical cost determination. For direct non-medical cost and indirect cost, a family member was interviewed. FINDINGS: It was found that 201 patients with β-thalassemia/Hb E (91%) and homozygous β-thalassemia (9%) were recruited for this study. Ninety-two (46%) were severe thalassemia and 109 (54%) were mild to moderate severity. The annual average cost of treatment was US$950; 59% was direct medical cost, 17% direct non-medical cost, and 24% indirect cost. The costs were differentiated by some potential predictors. Significant predictor variables were: hospital, health insurance scheme, blood transfusion pattern, and iron chelation drug use. CONCLUSIONS: The average annual cost per patient was calculated, and the cost model was estimated. These would be applied for national planning, economic evaluation of treatment and prevention interventions, and budget impact analysis. |
format | Text |
id | pubmed-2835719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28357192010-03-10 Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children Riewpaiboon, Arthorn Nuchprayoon, Issarang Torcharus, Kitti Indaratna, Kaemthong Thavorncharoensap, Montarat Ubol, Bang-on BMC Res Notes Short Report BACKGROUND: Hemoglobin E beta-thalassemia (β-thalassemia/Hb E) has a variable severity, and the cost of treatment has not been well studied. The aim of this study was to analyze the societal cost of caring for children with β-thalassemias in Thailand. The study was designed as a prevalence-based cost-of-illness analysis in a societal perspective. Medical records from three public hospitals of children aged 2-18 years with β-thalassemia/Hb E and homozygous β-thalassemia were reviewed for direct medical cost determination. For direct non-medical cost and indirect cost, a family member was interviewed. FINDINGS: It was found that 201 patients with β-thalassemia/Hb E (91%) and homozygous β-thalassemia (9%) were recruited for this study. Ninety-two (46%) were severe thalassemia and 109 (54%) were mild to moderate severity. The annual average cost of treatment was US$950; 59% was direct medical cost, 17% direct non-medical cost, and 24% indirect cost. The costs were differentiated by some potential predictors. Significant predictor variables were: hospital, health insurance scheme, blood transfusion pattern, and iron chelation drug use. CONCLUSIONS: The average annual cost per patient was calculated, and the cost model was estimated. These would be applied for national planning, economic evaluation of treatment and prevention interventions, and budget impact analysis. BioMed Central 2010-01-30 /pmc/articles/PMC2835719/ /pubmed/20181056 http://dx.doi.org/10.1186/1756-0500-3-29 Text en Copyright ©2010 Riewpaiboon et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/2.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Report Riewpaiboon, Arthorn Nuchprayoon, Issarang Torcharus, Kitti Indaratna, Kaemthong Thavorncharoensap, Montarat Ubol, Bang-on Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children |
title | Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children |
title_full | Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children |
title_fullStr | Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children |
title_full_unstemmed | Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children |
title_short | Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children |
title_sort | economic burden of beta-thalassemia/hb e and beta-thalassemia major in thai children |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835719/ https://www.ncbi.nlm.nih.gov/pubmed/20181056 http://dx.doi.org/10.1186/1756-0500-3-29 |
work_keys_str_mv | AT riewpaiboonarthorn economicburdenofbetathalassemiahbeandbetathalassemiamajorinthaichildren AT nuchprayoonissarang economicburdenofbetathalassemiahbeandbetathalassemiamajorinthaichildren AT torcharuskitti economicburdenofbetathalassemiahbeandbetathalassemiamajorinthaichildren AT indaratnakaemthong economicburdenofbetathalassemiahbeandbetathalassemiamajorinthaichildren AT thavorncharoensapmontarat economicburdenofbetathalassemiahbeandbetathalassemiamajorinthaichildren AT ubolbangon economicburdenofbetathalassemiahbeandbetathalassemiamajorinthaichildren |